InSite Vision, Inc.
Product Pipeline
Building for the Future
Our portfolio includes therapeutic and diagnostic products
in early and late-stage development.
DuraSite® technology
Building Confidence
The proven DuraSite technology platform can be customized to deliver a wide variety of novel drug candidates.
Strategy for growth
Building Partnerships
We are securing partnerships to commercialize AzaSite in the expanding worldwide market of ocular infection.

InSite Vision is building a rich product pipeline of innovative ophthalmic products, utilizing novel agents, powerful drug delivery platforms, and unique genomic technology. Currently, our primary focus is on developing product candidates for the treatment of ocular bacterial infection and inflammation.

Our lead product, AzaSite® (azithromycin ophthalmic solution) 1%, is an ocular anti-infective product that contains the drug azithromycin. AzaSite, which uses the DuraSite® technology platform, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis. Three other product candidates formulated with DuraSite, AzaSite Plus (ISV-502), AzaSite Xtra (ISV-405), and AzaSite Otic (ISV-016), are currently under development.

AzaSite Family

The AzaSite family currently includes AzaSite®, AzaSite Plus™, AzaSite Xtra™ and AzaSite Otic™—all of which have been formulated with the DuraSite® technology platform.

 
AzaSite® 1,2 (ISV-401)
For the treatment of bacterial conjunctivitis

1, 2

AzaSite Plus™(ISV-502)
Under development for the treatment of bacterial infection and inflammation (ophthalmic)
AzaSite Otic™(ISV-016)
Under development for the treatment of bacterial infections (otic)
AzaSite Xtra™(ISV-405)
Under development for the treatment of ocular infection.

Pending Collaboration3

 
ISV-205
Potential treatment (topical) for inflammation and analgesia
OcuGene®
Glaucoma genetic test—detects a genetic marker in the promoter region of the TIGR gene

Sold/Licensed

 
AzaSite® 1,2 (ISV-401)
For the treatment of bacterial conjunctivitis

1, 2

AquaSite®
For the treatment of dry eye; Licensed to CIBA Vision Ophthalmics
ISV-403
For the treatment of bacterial infection; Sold to Bausch and Lomb Incorporated
  1. The U.S. Food & Drug Administration (FDA) has approved InSite Vision’s New Drug Application (NDA) for AzaSite (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis.
  2. Inspire Pharmaceuticals (NASDAQ:ISPH) has the responsibility to commercialize AzaSite in the U.S. and Canada in accordance with a completed license agreement. Ongoing activities are focused on licensing AzaSite in markets outside of the U.S. and Canada.
  3. Further development pending collaboration agreement with as yet unidentified partners.